Association between SLCO1B1 rs4149056 and tegafur–uracil-induced hepatic dysfunction in breast cancer. (5th February 2019)

• Record Type: Journal Article
• Authors: Kamio, Hidenori; Uchiyama, Toshitaka; Kanno, Hitoshi; Onoe, Yoshiko; Saito, Kayoko; Kameoka, Shingo; Kamio, Takako; Okamoto, Takahiro
• Is Part Of: Pharmacogenomics. Volume 20:Number 5(2019)
• Page Start: 353
• Page End: 365
• Publication Date: 2019-02-05
• Subjects: breast cancer -- hepatic dysfunction -- pharmacogenomics -- single nucleotide polymorphism -- SLCO1B1 -- tegafur/uracil; Pharmacogenomics -- Periodicals; 615.1
• DOI: 10.2217/pgs-2018-0100
• Languages: English
• ISSNs: 1462-2416

Abstract

Aim: The aim of this study was to identify pharmacogenomic biomarkers to predict tegafur–uracil (UFT)-induced liver dysfunction.Patients & methods: A total of 68 patients, who were administered UFT, were evaluated using a two-step pharmacogenomics analysis.Results: The first screening revealed the association between five SNPs and UFT-induced hepatic dysfunction. In the second step, SLCO1B1 (rs4149056) was found to be the only SNP associated with UFT treatment-related elevation of aspartate aminotransferase (odds ratio: C/C vs T/T = 7.8, C/T vs T/T = 5.7; p = 0.037) and alanine transaminase (odds ratio: C/C vs T/T = 12.2, C/T vs T/T = 4.1; p = 0.034) levels.Conclusion: The SLCO1B1 polymorphisms are possible predictors of UFT treatment-related hepatic dysfunction.